Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade.

By P. Johnson, S. Berhane, Chiaki Kagebayashi, S. Satomura, M. Teng, H. Reeves, J. O’Beirne, R. Fox, A. Skowrońska, D. Palmer and 10 more. Journal of Clinical Oncology, 2015

2,392 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/e1c74a9898c567df9e0fc48a88ec4be99accdbf4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. D. Sarkar
2. Saranya Chidambaranathan-Reghupaty
3. P. Fisher

In Hepatology

1. D. Sarkar
2. Saranya Chidambaranathan-Reghupaty
3. P. Fisher

Citations in the corpus

• Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification (2020, methodology): “Another model called Albumin-Bilirubin (ALBI) score was introduced in February 2015 and uses serum albumin and bilirubin levels to assess liver function (Johnson et al., 2015).”
• AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma (2023, neutral): “[149] It also recognizes the heterogeneity among patients with BCLC Stage B and incorporates concepts of downstaging and stage migration over time.”